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ABSTRAK
Tujuan: mengetahui efektivitas penggunaan asam traneksamat, yang dikatakan dapat menurunkan mortalitas 
lebih baik daripada plasebo. Metode: melalui penelusuran literatur di Cochrane Library, PubMed, Clinical 
Key, EBSCO, Science Direct dan Proquest sesuai dengan pertanyaan klinis, didapatkan satu systematic review 
yang mengkaji tujuh randomized controlled trials. Melalui telaah kritis, disimpulkan bahwa artikel tersebut 
memenuhi kriteria validitas dan relevansi. Hasil: artikel tersebut menemukan bahwa tidak ada perbedaan yang 
jelas antara kelompok intervensi dengan kelompok placebo dalam hal mortalitas. Kesimpulan: asam traneksamat 
tidak direkomendasikan untuk menurunkan mortalitas pada pasien perdarahan gastrointestinal bagian atas.
Kata kunci: asam traneksamat, mortalitas, perdarahan gastrointestinal bagian atas.
ABSTRACT
Aim: to review the effectiveness of tranexamic acid therapy which has been proposed to reduce bleeding 
and in turn lower mortality rate. Methods: following literature searching based on our clinical question on 
Cochrane Library, PubMed, Clinical Key, EBSCO, Science Direct and Proquest, one systematic review that 
includes seven randomized controlled trials is obtained. The article meets validity and relevance criteria. 
Results: the systematic review found that there is no any clear evidence between intervention and control 
groups in term of mortality. Conclusion: the use of tranexamic acid to reduce mortality in patients with upper 
gastrointestinal bleeding is not recommended.
Key words: tranexamic acid, mortality, upper gastrointestinal bleeding.
INTRODUCTION
Upper gastrointestinal bleeding includes 
hemorrhage from the esophagus to the ligament 
of Treitz and has life-threatening potential.1,2 
UK National Audit in 2007 shows that peptic 
ulcers accounted for 36% of all causes of upper 
gastrointestinal bleeding.3 Common clinical 
manifestations are hematemesis, coffee-ground 
emesis and melena.4,5 Despite advances in 
therapy, mortality rate remains unchanged at 
7 to 10% due to advances in patient age, more 
co-morbid diseases, and recurrent bleeding.3,6
Biopsy samples from patients with gastric or 
duodenal ulcer showed a significant increase in 
fibrinolytic activity compared to patients without 
gastric or duodenal ulcer (p<0.05).7 Tranexamic 
acid is an anti-fibrinolytic agent that slows down 
the conversion of plasminogen to plasmin. 
Therefore, it prevents the breakdown of blood 
clots, resulting in hemostasis.5 Several hospitals 
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routinely use tranexamic acid for patients 
with upper gastrointestinal bleeding although 
guidelines have not generally recommended it.8 
Antifibrinolytic agents such as tranexamic acid 
are expected to reduce fibrinolytic activity, thus 
prevent recurrent bleeding and mortality.
CLINICAL QUESTION
A 59-year-old woman came to the emergency 
unit complaining of dark-colored vomit since one 
hour before admission. She also felt nauseau and 
heartburn along with passing black stools once. 
The patient had a history of dyspepsia since five 
years prior. Endoscopic examination found giant 
duodenal ulcer (Forest Ib) and erosive gastritis. 
Her physician recommended administration 
of intravenous tranexamic acid 500 mg thrice 
daily as a part of her upper gastrointestinal 
bleeding treatment. Thus, we formulate the 
following clinical question: In patients with 
upper gastrointestinal bleeding, does the use of 
tranexamic acid reduce mortality compare to 
without tranexamic acid?
METHODS
Literature searching was done on November 
17, 2013 in these databases: Cochrane Library, 
PubMed, Clinical Key, EBSCO, Science Direct 
and Proquest. Keywords used were “tranexamic 
acid”, “upper gastrointestinal bleeding” and 
“mortality”. The results are presented in Figure 
1.
“tranexamic acid ” AND “upper gastrointestinal bleeding” AND “mortality”
Cochrane
Library




n=13 n=1959 n=8 n=365 n=138n=12
Title and abstract screening (total n = 2.495)
Inclusion
• Randomized controlled trial
• English or Bahasa
• Mortality as outcome
Exclusion
• Animal or molecular study
• Pediatrics






Critical appraisal (Table 1)
“
Figure 1. Flow chart of literature searching
173
Nur Atikah                                                                                                                    Acta Med Indones-Indones J Intern Med
RESULTS
Four eligible articles consisting of two 
original articles and two systematic reviews were 
obtained. Among these articles, one systematic 
review study, Gluud et al.6, already covered the 
remaining available articles (Gluud et al8, Biggs 
et al9, Hawkey et al.10) with one systematic 
review (Gluud et al8) as an earlier version of the 
other systematic review (Gluud et al6). Table 
1 shows the process of critical appraisal based 
on guidelines by Center for Evidence-Based 
Medicine University of Oxford.
Gluud et al6 reviewed seven double-blind 
randomized controlled trials published from 
1973 to 2001. The sources of bleeding in these 
trials are peptic ulcers (mean proportion 59%, 
range 27% to 90%) and esophageal varices 
(mean proportion 8%, range 5% to 16%). Three 
trials use oral tranexamic acid only, whilst the 
remaining trials use intravenous tranexamic acid 
for a maximum of two days or until endoscopy 
was performed, followed by oral medication. 
Duration of treatment ranges from two to seven 
days with total daily dose ranges from 4 to 8 g. 
The total dose of tranexamic acid given for the 
entire treatment period ranges from 16 to 42 g.
Five of seven trials report to have lost-to-
follow-up subjects, while the remaining do 
not have any drop-out subjects. The number 
of patients initially randomized is 1645. One 
among five subjects (21%) was excluded after 
initial randomization due to lack of verified 
bleeding, presence of malignant disease, terminal 
illness, late administration of treatment, or late 
admission to the hospital. Worst case scenario 
and post hoc sequential analysis are performed 
to evaluate any potential influence of lost-to-
follow-up subjects.
As many as 41 of 829 patients (5%) in 
tranexamic acid group and 68 of 825 patients 
(8%) in placebo group passed away. Random 
effect model meta-analysis found that tranexamic 
acid reduces mortality (RR 0.61; 95% CI 0.42 
– 0.89; I2=0%). Regression analysis found no 
clear evidence of bias (p=0.527). Different result 
is obtained when the proportion of patients who 
were excluded after randomization is counted. 
Worst case scenario analysis found no clear 
differences between intervention and control 
groups in terms of mortality (RR 0.78; 95% CI 
0.58-1.05; I2=6%). In addition, post hoc analysis 
found that overall sequential results are not 
significant after repeated testing.
DISCUSSION
On tissue injury, activation of the coagulation 
cascade leads to the formation of thrombin, 
which cleaves fibrinogen to fibrin. These 
polymerize to form insoluble fibrin and produce 
a haemostatic seal on damaged blood vessel 
walls. The fibrinolytic system is activated by 
the deposition of fibrin and assists in keeping 
the vessel lumen open. Fibrinolysis occurs when 
plasminogen binds to lysine residues on the 
surface of fibrin and is converted to plasmin in 
the presence of plasminogen activator. Plasmin 
cleaves fibrin into fibrin degradation products 
that inhibit excessive fibrin formation.11
Lysis of a excessive formed fibrin clot is 
an likely to be important in the clinical setting 





























































































Gluud et al (2012) + + + + + + + + + 1a
+ stated clearly in the article; - not being done; ? not stated clearly
*appraisal guideline for systematic review was adopted from Center for Evidence Based Medicine University of Oxford
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of upper gastrointestinal bleeding.12 Previous 
studies had found that fibrinolytic activity has 
been detected in gastric and duodenal tissues 
which contain high concentration of plasminogen 
activators. Vreebur et al.7 found that mucosal 
fibrinolytic activity is enhanced in mucosal 
biopsies from patients with an ulcer with 
endoscopic sign of bleeding.7
Tranexamic acid is a synthetic lysine amino 
acid derivative that has antifibrinolytic activity 
which acts by blocking the lysine binding sites of 
the plasminogen molecule that are essential for 
its binding to fibrin. With its high affinity lysine 
binding site of plasminogen, tranexamic acid is 
expected to reduce recurrent bleeding on upper 
gastrointestinal bleeding.11 However, Gluud et 
al.6 found no clear evidence regarding the effect 
of tranexamic acid in reducing mortality in 
patients with upper gastrointestinal bleeding.6 
Study conducted by Patchett et al.12 found that 
gastric juice is also contributes to gastrointestinal 
bleeding. Pure gastric juice interferes with 
haemostatis both by delaying the rate of clot 
formation and by reducing the quality of the 
final clot formed. This study suggests that an 
acid dependent factor in gastric juice such as a 
gastric protease is responsible in impairing clot 
formation. Thus, although tranexamic acid may 
be capable of inhibiting the plasmin mediated 
pathway, it has no activity against non-specific 
protease mediated clot lysis in patients with 
upper gastrointestinal bleeding.
The systematic review conducted by Gluud 
et al.6 does not have enough information about 
the side effect of tranexamic acid. Although 
the study did not find significant correlation 
between tranexamic acid and the risk of 
thromboembolism events, the analysis does 
not have sufficient statistical power to make 
clear inferences. Theoretically, tranexamic 
acid increases the risk of thrombosis due to 
unopposed fibrin generation.
CONCLUSION
There is no clear evidence regarding the 
effect of tranexamic acid in reducing mortality 
in patients with upper gastrointestinal bleeding. 
Because of the limited validity of both internal 
and external evidence, additional randomized 
controlled trial is needed to establish the 
effect of tranexamic acid in combination with 
current clinical practice. Thus, the current 
use of tranexamic acid as routine therapy in 
upper gastrointestinal bleeding is still not 
recommended.
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